首页 > 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

英文 中文
Meloxicam. Meloxicam。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 Epub Date: 2019-12-12 DOI: 10.1016/bs.podrm.2019.10.006
Nasr Y Khalil, Khalid F Aldosari

Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.

美洛昔康是一种非甾体抗炎药(NSAID),是一种奥昔康衍生物:4-羟基-2-甲基- n -(5-甲基-2-噻唑基)- 2h -1,2-苯并噻唑-3-羧酰胺1,1-二氧化。它是环氧化酶-2 (COX-2)的选择性抑制剂。它用于类风湿关节炎,骨关节炎急性加重,强直性脊柱炎和青少年特发性关节炎的管理。单次口服剂量为7.5mg,必要时增加至每日最大15mg(老年人7.5mg)。它也可以通过直肠栓剂给予,剂量与口服剂量相似。据报道,美洛昔康的副作用与非甾体类抗炎药(NSAIDs)相似,如腹痛、贫血和水肿。严重胃肠道(GI)不良事件的风险也增加,包括溃疡和出血。本简介旨在讨论和解释美洛昔康的物理特性、专有和非专有名称。它还包括制备方法,热学和光谱行为,分析方法,药代动力学,代谢,排泄和药理学。
{"title":"Meloxicam.","authors":"Nasr Y Khalil,&nbsp;Khalid F Aldosari","doi":"10.1016/bs.podrm.2019.10.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.006","url":null,"abstract":"<p><p>Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"159-197"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Index 指数
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2020-01-01 DOI: 10.1016/s1871-5125(20)30010-8
{"title":"Index","authors":"","doi":"10.1016/s1871-5125(20)30010-8","DOIUrl":"https://doi.org/10.1016/s1871-5125(20)30010-8","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(20)30010-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56843391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cocrystal Systems of Pharmaceutical Interest: 2012-2014. 医药领域的共晶系统:2012-2014。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2018-12-21 DOI: 10.1016/bs.podrm.2018.11.004
Harry G Brittain

Developments in the field of pharmaceutical cocrystals have been documented in the form of chronological review articles, and the present review encompasses articles published during 2012, 2013, and 2014. Appropriate publications were drawn from the major physical, crystallographic, and pharmaceutical journals, being sorted according to the identity of the drug substance involved. This information is contained in tabular form, where the primary sorting has been by compound name and year of publication. For each entry, the table also contains the bibliographic citation to the paper, a complete list of the authors, and the title of the paper.

药物共晶领域的发展已经以时间顺序的综述文章的形式被记录下来,目前的综述包括2012年、2013年和2014年发表的文章。从主要的物理、晶体学和药学期刊中提取适当的出版物,并根据所涉及的原料药的特性进行分类。这些信息以表格形式包含,其中主要排序是按复合名称和出版年份进行的。对于每个条目,该表格还包含论文的参考书目、作者的完整列表和论文的标题。
{"title":"Cocrystal Systems of Pharmaceutical Interest: 2012-2014.","authors":"Harry G Brittain","doi":"10.1016/bs.podrm.2018.11.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.004","url":null,"abstract":"<p><p>Developments in the field of pharmaceutical cocrystals have been documented in the form of chronological review articles, and the present review encompasses articles published during 2012, 2013, and 2014. Appropriate publications were drawn from the major physical, crystallographic, and pharmaceutical journals, being sorted according to the identity of the drug substance involved. This information is contained in tabular form, where the primary sorting has been by compound name and year of publication. For each entry, the table also contains the bibliographic citation to the paper, a complete list of the authors, and the title of the paper.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"415-443"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Thiouracil: Comprehensive profile. 硫脲嘧啶:综合概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-01-10 DOI: 10.1016/bs.podrm.2018.11.006
Nasr Y Khalil, Haitham K AlRabiah, Mohammed S Almousa, Ahmed Bari, Hamad M Alkahtani

Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.

硫脲嘧啶,2-磺胺酰基- 1h -嘧啶-4- 1,已被用作抗甲状腺,冠状动脉血管扩张剂,并在充血性心力衰竭。它被发现会引起粒细胞缺乏症,并被怀疑是致畸和致癌的。由于其高频率的不良反应,特别是粒细胞缺乏症,它的使用被放弃,以支持其他毒性较小的药物,如丙硫脲嘧啶和甲巯咪唑。硫脲嘧啶既指由硫酸化尿嘧啶组成的特定分子,也指基于该结构的一系列分子。这个家族的一个重要成员是丙硫脲嘧啶,这是一种硫脲类抗甲状腺药物,通过阻断甲状腺激素的产生起作用;它也抑制外周甲状腺素脱碘为三碘甲状腺原氨酸。本简介旨在讨论和解释硫脲嘧啶和丙基硫脲嘧啶的物理和化学性质、专有和非专有名称。它还包括用途和应用,制备方法,热光谱行为和分析方法。此外,还讨论了丙硫脲嘧啶的代谢、排泄和药理学。
{"title":"Thiouracil: Comprehensive profile.","authors":"Nasr Y Khalil,&nbsp;Haitham K AlRabiah,&nbsp;Mohammed S Almousa,&nbsp;Ahmed Bari,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2018.11.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.006","url":null,"abstract":"<p><p>Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"293-331"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Paclitaxel. 紫杉醇。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-04-22 DOI: 10.1016/bs.podrm.2018.11.001
Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Eram El Tahir, Hamad M Alkahtani, Bushra T AlQuadeib

Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.

紫杉醇是第一种微管稳定剂,被认为是过去二十年来化疗领域最重要的进展。它被认为是最广泛使用的抗肿瘤药物之一,在包括乳腺癌、子宫内膜癌、非小细胞肺癌、膀胱癌和宫颈癌在内的几种癌症中具有广泛的活性。它也被用于治疗艾滋病相关的卡波西肉瘤作为二线治疗。紫杉醇的命名、配方、元素分析、外观、应用和用途的概述。此外,还阐述了其作用机制和耐药性、不同的剂型和药物制备方法。并对其x射线衍射图、药物溶解度、熔点、差示扫描量热和稳定性等理化性质进行了综述。并对药典法、分光光度法、色谱法等药物分析方法进行了讨论。
{"title":"Paclitaxel.","authors":"Fulwah Yahya Alqahtani,&nbsp;Fadilah Sfouq Aleanizy,&nbsp;Eram El Tahir,&nbsp;Hamad M Alkahtani,&nbsp;Bushra T AlQuadeib","doi":"10.1016/bs.podrm.2018.11.001","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.001","url":null,"abstract":"<p><p>Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"205-238"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sorafenib. 索拉非尼。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-01-18 DOI: 10.1016/bs.podrm.2018.11.003
Ahmed A Abdelgalil, Hamad M Alkahtani, Fahad I Al-Jenoobi

Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases. This study presents a comprehensive profile of sorafenib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography and high-performance liquid chromatography. Only few stability indicating methods were found for quantification of sorafenib after exposing tablet dosage form to various stress conditions such as hydrolysis, oxidation, thermal stress, photo and UV light. However, none of these described methods were made to separate and quantify the degradation products. Pharmacology studies including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 55 references.

Sorafenib (bay43 -9006),由拜耳公司以Nexavar®(美国)上市,是美国fda批准用于治疗不可切除的肝细胞癌和晚期肾细胞癌的抗癌药物。Sorafenib通过靶向RAF/MEK/ERK通路和受体酪氨酸激酶抑制肿瘤生长和血管生成。本研究介绍了索拉非尼的全面概况,包括详细的命名、配方、元素分析、制备方法、理化特性和分析方法(包括光谱、电化学和色谱分析方法)。光谱和光谱分析包括紫外/可见光谱、振动光谱、核磁共振光谱((1)H和(13)C NMR)和质谱。色谱分析方法包括薄层色谱法和高效液相色谱法。对于索拉非尼片剂剂型在水解、氧化、热应力、光和紫外光等各种应激条件下暴露后的定量测定,仅有几种稳定性指示方法。然而,这些方法都不能分离和量化降解产物。药理学研究包括药效学、作用机制、药代动力学和药物-药物相互作用。上述每一节均附有适当的表格和数字,并附55篇参考文献。
{"title":"Sorafenib.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani,&nbsp;Fahad I Al-Jenoobi","doi":"10.1016/bs.podrm.2018.11.003","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.003","url":null,"abstract":"<p><p>Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases. This study presents a comprehensive profile of sorafenib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography and high-performance liquid chromatography. Only few stability indicating methods were found for quantification of sorafenib after exposing tablet dosage form to various stress conditions such as hydrolysis, oxidation, thermal stress, photo and UV light. However, none of these described methods were made to separate and quantify the degradation products. Pharmacology studies including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 55 references.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"239-266"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contributors 贡献者
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 DOI: 10.1016/s1871-5125(19)30011-1
{"title":"Contributors","authors":"","doi":"10.1016/s1871-5125(19)30011-1","DOIUrl":"https://doi.org/10.1016/s1871-5125(19)30011-1","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s1871-5125(19)30011-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56842749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sucrose octaacetate. 蔗糖八乙酸酯。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-03-08 DOI: 10.1016/bs.podrm.2019.02.002
William Craig Stagner, Shalini Gaddam, Rudrangi Parmar, Ajay Kumar Ghanta

Sucrose octaacetate (SOA) is a United States National Formulary (NF) monograph compendial material (U.S. Pharmacopeia, 2008), and, as shown in Fig. 1, has eight acetate groups attached to a sucrose moiety. It is a natural product that has been extracted from the seeds of Annona cornifolia (Lima et al., 2011). It is nontoxic (Sigma-Aldrich, 2016) and has a number of uses based on its bitter taste. For example, sugar is rendered too bitter is eat at a concentration of 0.06% (w/w) SOA (Mann et al., 1992). SOA can form 255 different possible isomers and degradation products, all of which have a very low molar absorptivity. Its ultraviolet molar absorptivity at 210nm has been reported to be 439 absorption units/cm/M in water and 442 absorption units/cm/M in 30:70 acetonitrile-water.

八乙酸蔗糖(SOA)是美国国家处方(NF)专著药典材料(美国药典,2008),如图1所示,有八个醋酸基团连接到蔗糖部分。它是一种天然产品,从金叶番荔枝种子中提取(Lima et al., 2011)。它是无毒的(Sigma-Aldrich, 2016),并且基于它的苦味有许多用途。例如,当糖的浓度为0.06% (w/w) SOA时,糖会变得太苦(Mann et al., 1992)。SOA可以形成255种不同的异构体和降解产物,它们都具有非常低的摩尔吸收率。其在210nm处的紫外摩尔吸收率在水中为439个吸收单位/cm/M,在30:70的乙腈水中为442个吸收单位/cm/M。
{"title":"Sucrose octaacetate.","authors":"William Craig Stagner,&nbsp;Shalini Gaddam,&nbsp;Rudrangi Parmar,&nbsp;Ajay Kumar Ghanta","doi":"10.1016/bs.podrm.2019.02.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.02.002","url":null,"abstract":"<p><p>Sucrose octaacetate (SOA) is a United States National Formulary (NF) monograph compendial material (U.S. Pharmacopeia, 2008), and, as shown in Fig. 1, has eight acetate groups attached to a sucrose moiety. It is a natural product that has been extracted from the seeds of Annona cornifolia (Lima et al., 2011). It is nontoxic (Sigma-Aldrich, 2016) and has a number of uses based on its bitter taste. For example, sugar is rendered too bitter is eat at a concentration of 0.06% (w/w) SOA (Mann et al., 1992). SOA can form 255 different possible isomers and degradation products, all of which have a very low molar absorptivity. Its ultraviolet molar absorptivity at 210nm has been reported to be 439 absorption units/cm/M in water and 442 absorption units/cm/M in 30:70 acetonitrile-water.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"267-291"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Topiramate: Comprehensive profile. 托吡酯:综合概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-01-14 DOI: 10.1016/bs.podrm.2018.11.005
Nasr Y Khalil, Haitham K AlRabiah, Saad S Al Rashoud, Ahmed Bari, Tanveer A Wani

Topiramate, 2,3:4,5-di-O-isopropylidene-β-d-fructopyranose sulfamate, is a potent antiepileptic drug with a broad spectrum of activity. It is effective in both partial and generalized seizures. Topiramate was also found to have significant efficacy in migraine prevention with considerable reductions in the frequency of migraine headaches. The most common adverse events, which may accompany the use of topiramate, are paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease and taste perversion. The weight loss observed with the use of topiramate in obese, epileptic patients, afforded the approval of this drug as an anti-obesity medication. This action is thought to be based on the selective inhibition of mitochondrial carbonic anhydrase isoforms. This profile is prepared to discuss and explain physical characteristics, proprietary and nonproprietary names of topiramate. It also includes methods of preparation, thermal and spectral behavior and methods of analysis. Pharmacokinetics, metabolism, excretion and pharmacology together with its uses and applications are also discussed.

托吡酯(2,3:4,5-二- o -异丙基-β-d-果糖氨基磺酸)是一种具有广谱活性的有效抗癫痫药物。它对部分性和全身性癫痫发作都有效。托吡酯在预防偏头痛方面也有显著的疗效,可以显著降低偏头痛的发生频率。最常见的不良事件,可能伴随使用托吡酯,是感觉异常,疲劳,食欲下降,恶心,腹泻,体重减轻和味觉变态。在肥胖、癫痫患者中使用托吡酯观察到的体重减轻,给予了这种药物作为抗肥胖药物的批准。这种作用被认为是基于选择性抑制线粒体碳酸酐酶同工型。本简介旨在讨论和解释托吡酯的物理特性、专有和非专有名称。它还包括制备方法,热和光谱行为和分析方法。并讨论了其药代动力学、代谢、排泄和药理学及其用途和应用。
{"title":"Topiramate: Comprehensive profile.","authors":"Nasr Y Khalil,&nbsp;Haitham K AlRabiah,&nbsp;Saad S Al Rashoud,&nbsp;Ahmed Bari,&nbsp;Tanveer A Wani","doi":"10.1016/bs.podrm.2018.11.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.005","url":null,"abstract":"<p><p>Topiramate, 2,3:4,5-di-O-isopropylidene-β-d-fructopyranose sulfamate, is a potent antiepileptic drug with a broad spectrum of activity. It is effective in both partial and generalized seizures. Topiramate was also found to have significant efficacy in migraine prevention with considerable reductions in the frequency of migraine headaches. The most common adverse events, which may accompany the use of topiramate, are paresthesia, fatigue, decreased appetite, nausea, diarrhea, weight decrease and taste perversion. The weight loss observed with the use of topiramate in obese, epileptic patients, afforded the approval of this drug as an anti-obesity medication. This action is thought to be based on the selective inhibition of mitochondrial carbonic anhydrase isoforms. This profile is prepared to discuss and explain physical characteristics, proprietary and nonproprietary names of topiramate. It also includes methods of preparation, thermal and spectral behavior and methods of analysis. Pharmacokinetics, metabolism, excretion and pharmacology together with its uses and applications are also discussed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"333-378"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Cefpodoxime proxetil. 头孢泊肟酯。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2019-01-01 Epub Date: 2019-04-16 DOI: 10.1016/bs.podrm.2019.02.001
Gamal A E Mostafa, Yazeed H Al-Otaibi, Abdullah A Al-Badr

A comprehensive profile of cefpodoxime proxetil including the nomenclatures, formulae, elemental composition, appearance, uses, and applications. The methods which were developed for the preparation of the drug substance and their respective schemes are outlined. The physical characteristics of the drug including the ionization constant, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal behavior, and spectroscopic studies are included. The methods which were used for the analysis of the drug substance in bulk drug and/or in pharmaceutical formulations includes the compendial, spectrophotometric, electrochemical and the chromatographic methods. The other studies which was carried out on this drug substance are including the drug stability, pharmacokinetics, bioavailability, drug evaluation, comparison and several compiled reviews. Finally, more than two hundred references are listed at the end of this profile.

头孢泊肟酯的综合概况,包括名称、配方、元素组成、外观、用途和应用。概述了制备该药物的方法及其各自的方案。药物的物理特性包括电离常数、溶解度、X 射线粉末衍射图样、差示扫描量热法、热行为和光谱研究。用于分析散装药物和/或药物制剂中药物物质的方法包括药典法、分光光度法、电化学法和色谱法。对这种药物进行的其他研究包括药物稳定性、药代动力学、生物利用度、药物评价、比较和若干汇编综述。最后,本简介末尾还列出了 200 多篇参考文献。
{"title":"Cefpodoxime proxetil.","authors":"Gamal A E Mostafa, Yazeed H Al-Otaibi, Abdullah A Al-Badr","doi":"10.1016/bs.podrm.2019.02.001","DOIUrl":"10.1016/bs.podrm.2019.02.001","url":null,"abstract":"<p><p>A comprehensive profile of cefpodoxime proxetil including the nomenclatures, formulae, elemental composition, appearance, uses, and applications. The methods which were developed for the preparation of the drug substance and their respective schemes are outlined. The physical characteristics of the drug including the ionization constant, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal behavior, and spectroscopic studies are included. The methods which were used for the analysis of the drug substance in bulk drug and/or in pharmaceutical formulations includes the compendial, spectrophotometric, electrochemical and the chromatographic methods. The other studies which was carried out on this drug substance are including the drug stability, pharmacokinetics, bioavailability, drug evaluation, comparison and several compiled reviews. Finally, more than two hundred references are listed at the end of this profile.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"1-165"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Profiles of drug substances, excipients, and related methodology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1